within Pharmacolibrary.Drugs.ATC.C;

model C01CE04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01CE04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bucladesine (dibutyryl cyclic AMP) is a synthetic analog of cyclic adenosine monophosphate (cAMP) that acts as a phosphodiesterase-resistant cAMP derivative. It was investigated for its use as a vasodilator and in the treatment of heart failure and peripheral vascular diseases. It is not currently approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>No human pharmacokinetic parameter data are reported in the literature for bucladesine. The following represents an estimated one-compartment PK model for intravenous administration, reflecting typical parameters for small, hydrophilic nucleoside analogs. These figures are likely to be rough estimates and not derived from primary data.</p><h4>References</h4><ol><li><p>Mafune, E, Takahashi, M, &amp; Takasugi, N (1995). Effect of vehicles on percutaneous absorption of bucladesine (dibutyryl cyclic AMP) in normal and damaged rat skin. <i>Biological &amp; pharmaceutical bulletin</i> 18(11) 1539–1543. DOI:<a href=\"https://doi.org/10.1248/bpb.18.1539\">10.1248/bpb.18.1539</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8593475/\">https://pubmed.ncbi.nlm.nih.gov/8593475</a></p></li><li><p>Kucera, T, Jungermann, K, &amp; Stümpel, F (2000). Impaired stimulation of intestinal glucose absorption by portal insulin via hepatoenteral nerves in chronically ethanol-intoxicated rats. <i>FEBS letters</i> 474(2-3) 223–227. DOI:<a href=\"https://doi.org/10.1016/s0014-5793(00)01608-2\">10.1016/s0014-5793(00)01608-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10838089/\">https://pubmed.ncbi.nlm.nih.gov/10838089</a></p></li><li><p>Ikeda, H, Kurisu, K, &amp; Kihira, K (2004). Vancomycin ointment for MRSA infection at a cranioplasty site. <i>The Annals of pharmacotherapy</i> 38(1) 70–72. DOI:<a href=\"https://doi.org/10.1345/aph.1D178\">10.1345/aph.1D178</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14742798/\">https://pubmed.ncbi.nlm.nih.gov/14742798</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01CE04;
